Back to Search
Start Over
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
- Source :
-
Cancer cell [Cancer Cell] 2014 Jul 14; Vol. 26 (1), pp. 7-9. - Publication Year :
- 2014
-
Abstract
- In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.<br /> (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Class I Phosphatidylinositol 3-Kinases
Female
Humans
Antineoplastic Combined Chemotherapy Protocols pharmacology
Breast Neoplasms drug therapy
Cyclin-Dependent Kinase 4 antagonists & inhibitors
Cyclin-Dependent Kinase 6 antagonists & inhibitors
Mutation
Phosphoinositide-3 Kinase Inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1878-3686
- Volume :
- 26
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cancer cell
- Publication Type :
- Academic Journal
- Accession number :
- 25026206
- Full Text :
- https://doi.org/10.1016/j.ccr.2014.06.020